Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target

The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and po...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oral pathology & medicine 2018-08, Vol.47 (7), p.691-695
Main Authors: Yeoh, Chit Cheng, Dabab, Nedal, Rigby, Elyse, Chhikara, Ritu, Akaev, Iolia, Gomez, Ricardo Santiago, Fonseca, Felipe, Brennan, Peter A., Rahimi, Siavash
Format: Article
Language:English
Subjects:
abiraterone
Adenocarcinoma - diagnosis
Adenocarcinoma - drug therapy
Administration, Oral
Androgen Antagonists - administration & dosage
androgen receptor
Androgen receptors
Androgens
Androstenes - administration & dosage
Anilides - administration & dosage
Antineoplastic Agents - administration & dosage
Biomarkers, Tumor - analysis
Carcinoma, Adenoid Cystic - diagnosis
Carcinoma, Adenoid Cystic - drug therapy
Carcinoma, Mucoepidermoid - diagnosis
Carcinoma, Mucoepidermoid - drug therapy
Dentistry
enzalutamide
Female
head and neck
Humans
immunohistochemistry
Male
Molecular Targeted Therapy
Neck
Nitriles - administration & dosage
non‐squamous cell carcinoma
Oral cancer
Phenylthiohydantoin - administration & dosage
Phenylthiohydantoin - analogs & derivatives
Receptors, Androgen - analysis
Salivary Ducts
Salivary gland
salivary gland carcinoma
Salivary Gland Neoplasms - diagnosis
Salivary Gland Neoplasms - drug therapy
Squamous cell carcinoma
Tosyl Compounds - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.
ISSN:0904-2512
1600-0714
DOI:10.1111/jop.12741